Abivax sets its course on colitis and Crohn’sFrench biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 Share XAbivax sets its course on colitis and Crohn’shttps://pharmaphorum.com/news/abivax-scolitis-crohns/
Takeda finalises buyout of TiGenixJapanese pharma giant Takeda has completed its buyout of TiGenix. Takeda’s main R&D focus is in oncology, gastroenterology Share XTakeda finalises buyout of TiGenixhttps://pharmaphorum.com/news/japanese-takeda-finalises-tigenix-boyout/
Pioneering Crohn’s antibiotic treatment meets early targetA drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial. Share XPioneering Crohn’s antibiotic treatment meets early targethttps://pharmaphorum.com/news/pioneering-crohns-antibiotic-treatment-meets-early-target/
First ever ‘off the shelf’ stem cell therapy nears European approvalAlofisel recommended for complex perianal fistulas in Crohn’s disease Share XFirst ever ‘off the shelf’ stem cell therapy nears European approvalhttps://pharmaphorum.com/news/tigenixtakeda-stem-cell-therapy-backed-eu-regulators/
Janssen inks potential $1bn deal for IBD drugJanssen has swooped to buy rights to an early-stage oral inflammatory bowel disease drug from Protagonist Therapeutics in Share XJanssen inks potential $1bn deal for IBD drughttps://pharmaphorum.com/news/janssen-inks-potential-1bn-deal-ibd-drug/
